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Abstract
Chagas disease remains one of the most neglected diseases in the world despite being the
most important parasitic disease in Latin America. The characteristic chronic manifestation of
chagasic cardiomyopathy is the region’s leading cause of heart-related illness, causing signif-
icant mortality and morbidity. Due to the limited available therapeutic options, new drugs are
urgently needed to control the disease. Sirtuins, also called Silent information regulator 2
(Sir2) proteins have long been suggested as interesting targets to treat different diseases,
including parasitic infections. Recent studies on Trypanosoma cruzi sirtuins have hinted at
the possibility to exploit these enzymes as a possible drug targets. In the present work, the T.
cruzi Sir2 related protein 1 (TcSir2rp1) is genetically validated as a drug target and biochemi-
cally characterized for its NAD+-dependent deacetylase activity and its inhibition by the clas-
sic sirtuin inhibitor nicotinamide, as well as by bisnaphthalimidopropyl (BNIP) derivatives, a
class of parasite sirtuin inhibitors. BNIPs ability to inhibit TcSir2rp1, and anti-parasitic activity
against T. cruzi amastigotes in vitro were investigated. The compound BNIP Spermidine
(BNIPSpd) (9), was found to be the most potent inhibitor of TcSir2rp1. Moreover, this com-
pound showed altered trypanocidal activity against TcSir2rp1 overexpressing epimastigotes
and anti-parasitic activity similar to the reference drug benznidazole against the medically
important amastigotes, while having the highest selectivity index amongst the compounds
tested. Unfortunately, BNIPSpd failed to treat a mouse model of Chagas disease, possibly
due to its pharmacokinetic profile. Medicinal chemistry modifications of the compound, as
well as alternative formulations may improve activity and pharmacokinetics in the future.
Additionally, an initial TcSIR2rp1 model in complex with p53 peptide substrate was obtained
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Author summary
Trypanosoma cruzi is a protozoan parasite belonging to the Kinetoplastida class responsi-
ble for Chagas disease, a neglected tropical illness that affects an estimated 6 to 8 million
people in Latin America and some Southern regions of the USA, with another 25 million
at risk of acquiring the disease and a death toll of 12,000 every year. Commonly transmit-
ted from the feces of the kissing bug, the disease is characterized by a nearly asymptomatic
acute phase but a problematic chronic phase in which 20–30% of individuals develop seri-
ous cardiac and/or intestinal problems. The therapies currently in use were introduced
more than forty years ago, and there are important concerns about adverse effects and
lower effectiveness with disease progression. There is, therefore, an urgent need to find
better alternatives. In this study, we evaluate the potential of a Trypanosoma cruzi sirtuin
protein as a novel drug target and its inhibition by novel members of a known class of sir-
tuin compound inhibitors.
Introduction
Chagas disease, caused by the protozoan Trypanosoma cruzi, remains one of the most prevalent
and neglected diseases in the world [1] and is the parasitic disease with the highest socio-economic
burden in Latin America [2, 3]. More recently, Chagas disease has also emerged as a significant
public health concern imparting a serious burden of disease in some Southern regions of the USA
[4]. While the vast majority of the newly acquired cases are asymptomatic, about 20 to 30% of the
cases lead to the development, usually decades later, of the characteristic chronic chagasic cardio-
myopathy that is the leading cause of non-ischemic heart disease in South America [5, 6].
Although vectorial transmission has been greatly reduced in recent years, mainly due to
improved housing and awareness, other transmission mechanisms like congenital or oral
transmission, blood transfusion and organ transplantation still contribute to about 40,000 new
cases and 12,000 deaths every year [7]. What used to be a local concern, has become a world-
wide problem due to human migrations to other parts of the world such as North America,
Europe and Japan [8].
With no available vaccine for Chagas disease therapies rely upon two drugs introduced
more than 40 years ago: benznidazole and nifurtimox. These drugs are far from ideal because
of their many toxic side-effects and the requirement of long periods of administration [4, 9,
10]. Thus, there is an urgent need for new drugs. Very few candidates have populated the drug
discovery pipeline for Chagas disease in the past decade, and most have the same mechanism
of action [11]. The recent failure in clinical trials of two of these drugs, posaconazole and
E1224, has exposed the fragilities of the chemotherapeutic pipeline and reinforced the need for
constant drug discovery efforts to find novel alternative targets and therapies [12–14].
Sir2 (silent information regulator 2) or sirtuins are class III histone deacetylases that are
evolutionary conserved and present across various kingdoms of life, from bacteria to humans
[15, 16]. They catalyse the NAD+- dependent deacetylation of acetylated lysine residues in a
polypeptide chain, according to the following reaction:
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Acetylated-Protein + NAD+!Deacetylated Protein + 2’-O-AADPr + Nicotinamide
Besides the deacetylated lysine, other products are formed in the reaction, like nicotinamide
(an endogenous inhibitor) and 2’-O-acetyl-ADP-ribose (2’-O-AADPr), that has been sug-
gested to act as a secondary messenger [17], promoting the association between Sir3/Sir2/Sir4
involved in yeast gene silencing [18]. Some human sirtuins like SIRT4 and SIRT6 and the pro-
tozoan Sir2 related protein 1 (Sir2rp1) from Trypanosoma brucei and Leishmania infantum
also display ADP-ribosyltransferase activity [19–22]. However, the biological role of ADP-
ribosylation by sirtuins has not been clearly demonstrated and is currently debated to be a
non-specific side reaction [23]. In addition, some sirtuins have been characterized to perform
demalonylase, desuccinylase and deglutarylase activity [24, 25].
Sirtuins have been attributed many roles in different organisms, including life span regulation,
cell cycle progression, gene transcription, apoptosis, DNA repair and metabolism [26–29]. The
human genome, as well as other mammals’ genomes, codify 7 distinct sirtuins (SIRT1-7) [30],
whose proteins are distributed in different cell compartments: SIRT1, SIRT6 and SIRT7 are
located in the nucleus, SIRT2 is cytoplasmic (but shuttles to and from the nucleus), whereas
SIRT3, SIRT4 and SIRT5 are found in the mitochondria [31]. Their different localizations are
related with their cellular functions, for instance: nuclear SIRT1, 6 and 7 are involved in transcrip-
tion regulation [32], DNA repair [33, 34] and chromatin remodeling [35, 36], respectively; SIRT2
is a tubulin deacetylase that co-localizes with the cytoskeleton, but is imported to the nucleus,
where it participates in cell cycle regulation [37]; and mitochondrial SIRT3, 4 and 5, participate in
fatty acid metabolism [38], amino acid metabolism [19] and the urea cycle, respectively [39].
By contrast, parasitic protozoa have fewer sirtuin homologues, but they have also been
described as “pro-life” proteins due to their importance for the normal development and func-
tioning of these cells. For instance, in the apicomplexan Plasmodium falciparum, Sir2A and B
are involved in antigenic variation, an essential process for immune system evasion [40, 41].
Trypanosomatids have two to three homologues (Sir2rp1-3) with some of the members vary-
ing in their functions and subcellular localizations. T. brucei Sir2rp1 is the most characterized
of the three enzymes, and is located in the nucleus and seems to be important for the protec-
tion against DNA damage [21, 42]. TbSir2rp2 and TbSir2rp3 are localized in the mitochondria
and little is known about their function, except that they are not essential for parasite survival
[42]. Leishmania species also encode for three sirtuin enzymes, but most studies are focused
on Sir2rp1, that has a cytoplasmic localization. Sir2rp1 from L. infantum is required for the
normal replication of amastigotes [43]. T. cruzi genomes sequenced so far, have only revealed
two homologues, Sir2rp1 and Sir2rp3, which are localized in the cytoplasm and the mitochon-
dria, respectively [44, 45]. Overexpression of either TcSir2rp1 or TcSir2rp3 showed them to
interfere with epimastigote growth, differentiation into metacyclic trypomastigotes, infectivity
of host cells and intracellular amastigote replication [44, 45]. It should be noted that some con-
tradictory findings have been reported by both research groups, differences that are likely
related with the strategy of overexpression (constitutive [44] versus inducible [45]). A clearer
role of the participation of Sir2rp1 and Sir2rp3 in T. cruzi life cycle and infectivity by gene
knockout studies awaits investigation.
Here, we characterize for the first time the enzymatic NAD+-dependent deacetylase activity
of TcSir2rp1 and show that as well as being hindered by classic inhibitors, bisnaphthalimido-
propyl (BNIP) derivatives [46], some showing specific “on target” trypanocidal activity against
T. cruzi epimastigotes are also effective inhibitors. Furthermore, we demonstrate that these
inhibitors are also active against the medically relevant stage of T. cruzi, intracellular amasti-
gotes, suggesting that TcSir2rp1 may be a viable drug target to explore for the chemotherapeu-
tic control of Chagas disease. In addition, the in vivo activity of the most potent inhibitor and
selective compound towards T. cruzi was evaluated by bioluminescence imaging.
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Methods
Ethics statement
All experiments involving animals were carried out in accordance with the IBMC.INEB Ani-
mal Ethics Committees and the Portuguese National Authorities for Animal Health guidelines,
according to the statements on the directive 2010/63/EU of the European Parliament and of
the Council.BPC and ACdS are accredited for animal research (Portuguese Veterinary Direc-
tion—DGAV, Ministerial Directive 113/2013). DGAV approved the animal experimentation
presented in this manuscript under the license number 0421/000/000/2013, from 1i3S–Insti-
tuto de Investigac¸ão e Inovac¸ão em Sau´de, Universidade do Porto, Porto, Portugal; 2IBMC-In-
stituto de Biologia Molecular e Celular, Parasite Disease Group, Porto, Portugal.
Cells and parasites
Mouse myoblast C2C12 cell line (ATCC) and green monkey kidney epithelial Vero cells
(ATCC) were cultured with high glucose DMEM, supplemented with 10% FBS (Gibco), 25
mM HEPES, 2 mM glutamine, 100 U/mL penicillin, 100 U/mL streptomycin and maintained
in a humid 5% CO2 atmosphere at 37˚C.
T. cruzi epimastigotes of the strain CL-Brener were maintained in the logarithmic phase of
growth (1.0 x 106–1.0 x 107 cells / mL) at 28˚C in RTH/FCS medium (RPMI 1640 supplemented
with trypticase, haemin, HEPES, and 10% FBS (Invitrogen)). For the generation of transgenic cell
lines, 15 μg of the constructs were digested overnight (SpeI for the pTcINDEX construct; NotI for
the knockout constructs), precipitated with sodium acetate / ethanol, and introduced into 1.5 x 107
epimastigote cells in the logarithmic phase of growth via transfection using an AMAXA Nucleofec-
tor II device (program V-33) with the Human T-cell nucleofector kit (Lonza). Parasites were sus-
pended in fresh growth medium and incubated for 24-hrs to allow for the expression of drug
selectable markers, prior to the addition of appropriate antibiotic (Blasticidin S (Thermo Fisher
Scientific; 10 μg/mL); Hygromycin B (Formedium; 100 μg/mL); and Puromycin (Calbiochem;
5 μg/mL). Cells were then incubated for a further four- to six-weeks to allow for the selection of
transgenic parasites and then genetically verified by PCR using ORF and drug selection primers.
T. cruzi wild-type (wt) and luciferase-expressing (Luc+) Y strain trypomastigotes (made in
house) were maintained by in vitro infection of a monolayer of Vero cells and harvested by col-
lection of the supernatant after 5 to 7 days. The trypomastigotes were used for the in vitro
screening and to re-infect new monolayers for up to 10 cycles, after which point the cultures
were rejected and restarted from a new frozen stock. Luminescent Y strain parasites were
obtained by transfection as previously described [47]. Briefly, 10 μg of the overexpression plas-
mid pTREX [48], containing the sequence for firefly luciferase, were transfected into logarith-
mic Y strain as described above. Twenty-four hours after transfection, 75 μg/mL of G418 was
added to the culture and parasites were selected for 6 weeks. Epimastigotes cultures were
allowed to enrich for metacyclic trypomastigotes for 3 weeks, after which the parasites were
used to infect monolayers of Vero cells in the presence of G418.
Generation of ectopic / overexpression and knockout constructs
The TcSir2rp1 open reading frame (TriTryp accession number TcCLB.508207.150) was ampli-
fied from CL-Brener genomic DNA using KOD polymerase (Novagen). The resulting PCR
product encoding the full-length ORF was cloned directly into the T. cruzi expression vector,
pTcINDEX [49], using NotI and BamHI restriction sites.
To construct gene replacement cassettes, the 5’ and 3’ UTR regions adjacent to the
TcSir2rp1 ORF (~500 bp) were PCR amplified from genomic DNA (S1 Fig for sequences),
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stitched together in a ‘knitting’ PCR reaction before ligating into the pGEM-5Zf(+) vector
(Promega) via NotI restriction sites. Following this, the antibiotic resistance markers blastici-
din-S (BSD) and puromycin N-acetyltransferase (PAC) were cloned into the stitch sequence
BamHI / HindIII sites located between the adjoining UTRs. In order to validate the genetically
modified T. cruzi cell-lines generated by previously described gene knock -in / -out experi-
ments and further determine the relative gene expression levels of TcSir2rp1; a quantitative
reverse transcription-PCR (qRT-PCR) study was performed. qPCR primers were designed,
and initially normalized against two constitutively expressed, previously published and verified
T. cruzi housekeeping / reference genes: histone H2B (TcCLB.511635.10) of the core nucleo-
some structure and glyceraldehyde-3-phosphate dehydrogenase (TcCLB.506885.413). DNase
treated RNA was used as the template for a two-step reverse transcription reaction to generate
complementary DNA, which in turn was utilized in a quantitative PCR reaction with detection
through SYBR Green dye fluorescence.
Cloning, expression and purification of recombinant TcSir2rp1
The full coding sequence of TcSir2rp1 was PCR amplified using the primers 5’-CCATGGGAA
TGAATCAAGATAACGCCAACTTT-3’ and 5’-CTCGAGTTTTCGGTCTGTCTGTGTGTA
CATG-3’ and ligate into pET-28a (Novagen) using the NcoI and XhoI restriction sites. Recom-
binant expression of the C-terminal His-tagged protein was achieved in BL21 (DE3) by induc-
tion with 0.5 mM IPTG (isopropyl-β-D-thiogalactopyranoside) overnight at 18˚C. Pelleted
cells were suspended in 500 mM NaCl, 20 mM Tris.HCl, pH 7.6 and disrupted by probe soni-
cation and cleared by centrifugation. The Ni2+-NTA purified protein was buffer exchanged to
PBS via a PD-10 desalting column (GE Healthcare) and aliquots were stored at -70˚C prior to
use for enzymatic assays. Protein was Western blotted using a rabbit polyclonal anti-HisTag
antibody in a dilution of 1:1000. For crystallography, the full length TcSir2rp1 (M1-K359)
was cloned into an in-house modified pET-28b vector, where the thrombin cleavage site is
replaced by a tobacco etch virus (TEV) cleavage site and verified by sequencing. Expression of
TcSir2rp1 was performed in BL21(DE3) in auto induction medium at 18˚C overnight. Spun
down bacterial cells were suspended in lysis buffer (50 mM Tris.HCl (pH 7.5), 500 mM NaCl,
1 mM dithiotreitol (DTT), 2mM n-octyl β-D-glucopyranoside (n-OG) and 20 mM imidazole
supplemented with protease inhibitor cocktail. Soluble tagged protein was recovered from the
supernatant following centrifugation of the cell homogenate by affinity chromatography on
His60 Ni Superflow Resin (Clontech). Lysis buffer was used to wash the resin and protein was
eluted by buffer A (50 mM Tris.HCl (pH7.5), 500 mM NaCl, 1 mM DTT, 2 mM n-OG and
500 mM imidazole). Recombinant TEV was used to remove the tag (overnight incubation at
4˚C). The second purification step consisted of anion exchange chromatography (HiTrap Q
HP 1 mL) with an increasing NaCl gradient in 50 mM Tris.HCl (pH 7.5), 2 mM n-OG and 1
mM DTT. Protein eluted at around 150 mM NaCl. Fractions containing pure protein were
pooled and the protein was concentrated to ~9 mg/mL.
T. brucei Sir2rp1 (accession number: AAX70528.1) tagged with a C-terminal hexahistidine
was expressed and characterized essentiality as described previously [50] L. infantum Sir2rp1
was expressed and purified as previously described [22].
Deacetylation assays
The deacetylase activity was measured using the commercial SIRT1/Sir2 Deacetylase Fluoro-
metric Assay Kit (CycLex,Japan) according to the manufacturer’s recommendations. Briefly,
fluorescence emission after digestion of deacetylated substrates by a lysine specific endopepti-
dase was measured in a fluorometric plate reader (Synergy HT, BioTek) with excitation and
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emission wavelengths set at 340 and 440 nm, respectively, every 30 seconds for 1 hour. The
slope of the linear part of the reaction was calculated and used as readout of enzyme activity.
Kinetic constants were determined with 0.5 μg of TcSir2rp1. For the determination of the
peptide substrate constants, NAD+ concentration was fixed at an excess of 2000 μM while the
peptide substrate concentration was varied between 0.63 and 40 μM. For the NAD+ constants,
the peptide substrate concentration was kept in excess at 40 μM while NAD+ concentration
was varied from 15.63 to 2000 μM. Initial velocities were measured between 4 and 6 minutes
where steady state conditions were assumed. Data was analysed with GraphPad Prism version
6.0 software using the built-in enzyme kinetics, Michaelis-Menten equation regression for Km
and Vmax determinations. kcat was calculated from the total enzyme concentration [E]t accord-
ing to the formula in
kcat ¼
Vmax
½Et
Eq 1
Potential inhibitors, including newly synthesized BNIP derivatives, were tested using 200 μM
NAD+ and 10 μM of peptide substrate as previously described [46]. The inhibition is expressed
in percentage and was calculated as the ratio of velocity for the linear portion of the reaction,
normalized with a no drug control and a reference drug control (nicotinamide at 2 mM).
Synthesis of BNIP derivatives
The following compounds were synthesized as previously reported 1–11 [46,51], 6b and 9a
[52], and 6c [53]. Compounds 1a-c, 6a, 7a 12 and 13 are newly synthetized in this study, see
supporting information file for details.
Screening of enzyme inhibitors
A variety of the bisnaphthalimidopropyl (BNIPs) derivatives, as well as the newly synthetized
derivatives were evaluated as potential TcSir2rp1 inhibitors. The enzymatic reactions were per-
formed using a commercially available CycLex SIRT1/Sir2 deacetylase fluorimetric kit (CycLex
Co. Ltd., Nagano, Japan) in the absence and presence of the various inhibitors, 200 μM NAD+
and 10 μM of peptide substrate as previously described [46]. The inhibition is expressed in per-
centage and was calculated as the ratio of velocity for the linear portion of the reaction, nor-
malized with a no drug control and a reference drug control (nicotinamide at 2 mM).
Crystallization, data collection and processing
Prior to crystallization, purified TcSir2rp1 was incubated with three molar equivalents of acet-
ylated p53 peptide (372-KKGQSTSRHK-K[Ac]-LMFKTEG-389). Co-crystallization experi-
ments were carried out using the sitting drop vapor diffusion method in 96-well plates using
an Innovadyne nanodrop robot. Crystals were grown in drops composed of 300 nL protein/
p53 mixture and 300 nL crystallization condition (100 mM MES pH 6.5 and 1.6 M MgSO4) at
4˚C. Crystals were flash-frozen in liquid nitrogen in crystallization condition supplemented
with 25% glycerol. Diffraction data were collected on Proxima 2 beamline (SOLEIL, Saclay,
France) on a Dectris Eiger 9M detector. Data were processed with xds [54] and CCP4 software
package [55].
TcSir2rp1 protein structural model
An initial TcSir2rp1 structure was obtained by molecular replacement with MrBump [56]
using an “in-house” determined LiSir2rp1 structure (pdb: 5Ol0) (Ronin et al manuscript
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submitted). Refinement of the TcSir2rp1 model was done by iterative cycles of building with
coot [57] and refinement with refmac [58]. The TcSir2rp1 3.5 Å structure consists of Chain
A = TcSir2rp1: H10-I56 + Y63-T251 + C299-G332 + 1 Zinc ion and Chain B = Peptide p53:
R379HKK(Ac)LMFK386. (SPG = P6322, Rcryst = 21.13% / Rfree = 28.05%, global high B value
112 Å2).
Molecular docking studies
The 3.5 Å crystal structure of TcSir2rp1 was used for docking of compounds 9, 1a and 1b.
Additionally, crystal structures of human SIRT2 were downloaded from the RCSB Protein
Data Bank [59] (3zgo, [60]; 4rmj, [61]; 4rmg, [62]. AutoDock Tools version 1.5.6 was used to
prepare the protein model for docking [62]. We used the protein models with and without
ligands (an acetylated fragment of p53 for TcSir2, ADP and nicotinamide for 4rmj, NAD+ and
SirtReal for 4rmg). Water molecules were removed, polar hydrogens added, charges for the
protein calculated and a pdbqt file for each protein model produced. Coordinates for the dock-
ing search grid were also determined. Ligands were prepared for docking by drawing their
structures in Chem3D, optimising mm2, and writing the structures to pdb files. AutoDock
Tools were then used to produce a PDBQT file for each ligand [63]. Docking was performed
with AutoDock Vina [64]. PyMOL (version 1.5.0.4, [65]) was used to visualize the molecular
models.
Anti-Trypanosoma cruzi assays
T. cruzi epimastigotes were seeded at 1.25 x 106 cells/mL in a 96-well plate in the presence of
varying concentrations of test compounds. Following a 64-hour incubation, 15 μL of a resa-
zurin solution (Sigma-Aldrich; 1.1 mg/mL in PBS). Following an additional 6-hr incubation,
cell viability was determined by measuring the fluorescence of each culture with a BioTek
FLX800 Fluorescence Microplate Reader (excitation and emission wavelengths of 540/535 nm
and 590/610 nm, respectively) and associated Gen5 Reader Control 2.0 software. EC50 values
were determined by nonlinear regression to a sigmoidal dose-response curve using GraFit
software (Version 5.0, Erithacus Software). Each assay was performed in at least triplicate in
parallel to the known trypanocidal agent nifurtimox.
For the evaluation of the activity against T. cruzi amastigotes, high-content screening
(HCS) was designed. In summary, 100 μL of host C2C12 cells (ATCC) were seeded in clear
bottom black 96-well plates at a density of 2.5 x 104 cells/mL (2.5 × 103 cells/well). After 24 hrs,
50 μL of Y strain tissue culture-derived trypomastigotes were used to infect the host cells at a
density of 7.5 x 105/mL (3.75 x 104 parasites/well). The parasites were allowed to infect for a 24
hr period, after which compounds were added in a volume of 50 μL. Final concentration of
DMSO in the assay did not exceeded 0.5%. After 72 hrs of compound incubation, the wells
were fixed with 4% paraformaldehyde for 15 to 30 mins. The plates were then washed once
with deionized water and stained with a solution of DAPI (3 μM) for 1 hour. Plates were
imaged in an INCell 2000 (GE Healthcare) high-content analyser by taking 16 pictures per
well at 20 X objective amplification. Images were analysed with INCell Developer software
(GE Healthcare) using the segmentation of host cell nuclei and parasite kinetoplast DNA. The
measurement output used was the average number of parasites per cell calculated by the ratio
of host cell nuclei/parasite kinetoplast DNA.
In vitro toxicity assays
To evaluate toxicity towards mammalian cell lines (hepatocytes (Seralab), neurons and MDCK
cells (ATCC); a renal cell line from dogs), all the compounds were assayed with MTT [66].
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Additionally, for cardiotoxicity evaluation, where toxic effects in cardiomyocytes could be
affecting their function before being lethal, a hERG assay was performed according to the
manufacturer’s protocol Predictor hERG Fluorescence Polarization Assay (Invitrogen).
Briefly, inhibition of hERG channel was analysed by competition of BNIPSpd and a high-affin-
ity red fluorescent hERG channel ligand. BNIPSpd (9) was mixed with the ligand and mem-
branes containing hERG channel, incubated for 2 hrs at RT and the fluorescence polarization
was measured using 530 / 590 nm ex/em filters using the Synergy 2 plate reader (Biotek).
In vitro assays were also performed in primary cells (hepatocytes and neurons) to evaluate
BNIPSpd (9) potential toxicity: (a) host cell nuclei counting after HOECHST staining, (b) via-
bility by measuring the metabolism of WST-8 probe, (c) apoptosis induction through caspase
3/7 activation, (d) evaluation of mitochondrial dysfunction by measuring the membrane
potential using TMRM probe, (e) membrane integrity by measuring the extracellular LDH, (f)
DNA damage by histone H2AX phosphorylation (exclusively in hepatocytes) and (g) imaging
of neurite outgrowth (exclusively in neurons).
The assays were performed 24 hrs after cell collection and isolation. For apoptosis, TMRM,
HOECHST and WST-8 assays, cells were seeded at a density of 5000 cells/well in coated
96-well plates, incubated for 24 hrs with the compound and then stained during 1 hour with
the following fluorescent probes: 5 μM CellEvent Caspase 3/7 Green Detection Reagent (Invi-
trogen) for measuring caspase 3/7 activation, 50 μM tetramethyl rhodamine methyl ester
(TMRM probe, Anaspec Inc.) for measuring mitochondrial depolarization related to transient
cytosolic Ca2+ signals, 5 μg/mL of HOECHST (Sigma-Aldrich) for nuclei detection and 10 μL/
well of WST-8 reagent (Sigma-Aldrich) to detect viable cells. Then, absorbance at 450 nm was
measured in order to analyse cell viability (WST-8). Cells were washed three times and ana-
lysed using the automatic fluorescence microscope BD Pathway 855. Pictures were taken using
a 20 X objective and 488/515 nm ex/em filters for CellEvent Caspase 3/7 reagent, 555/ 645 nm
ex/em filters for TMRM and 380/460 nm ex/em filters for HOECHST. Data were analysed
with AttoVision (Becton Dickinson). The LDH assay was performed according to the manu-
facturer’s protocol, Cytotoxicity Detection Kit LDH (Roche). LDH release was measured in
mU/L in culture media obtained from cells subjected to treatments for 24 hrs, by measuring
the released LDH rate of oxidation of NADH to NAD+ at 340 nm using Synergy 2 from
BioTech.
For the neurite outgrowth assay, samples were washed with PBS, fixed using methanol for
10 mins at -20˚C. The fixed samples were washed three times with PBS and permeabilized
with PBS-Triton X-100 0.3% for 10 mins, washed three times and then blocked with BSA 0.5%
in PBS for 30 mis. Anti-tubulin III antibody (Sigma-Aldrich) was added at 1/1000 dilution in
blocking solution and incubated for 60 minutes at room temperature. After three washing
steps, a secondary antibody Alexa 488 was added at 1/100 and incubated for 60 mins. After
washing three times with PBS, pictures were taken using the BD Pathway 855 automated fluo-
rescent microscope at 488/515 nm ex/em. Neurite average length was calculated using the
neurite outgrowth module of AttoVision software (Becton Dickinson).
DNA damage was evaluated by washing cells with PBS and fixation using paraformalde-
hyde 3% in PBS for 15 mins. After which they were washed three times with PBS, permeabi-
lized with PBS-Triton X-100 0.3% for 10 mins, washed again prior to blocking with PBS-BSA
0.5% for 30 mins. H2AX antibody (Abcam) was added at 1/400 in PBS-BSA 2.5% and incu-
bated for 60 mins at RT. After three washing steps, the secondary antibody Alexa 488 was
added 1/100 and incubated for 60 mins. After washing three times with PBS, pictures were
taken using the BD Pathway 855 automated fluorescent microscope at 488/515 nm ex/em fil-
ters. To determine the DNA damage, intensity in the nuclei was analyzed using AttoVision
software (Becton Dickinson).
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Nimesulide (400 μM) was included as a positive toxicity control, and the vehicle as a nega-
tive control. The relative percentage of deviation from the negative control was quantified and
assigned with a number from 0 to 5 according to the following criteria: 0 (0–20% deviation), 1
(20–40%), 2 (40–60%), 3 (60–100%), 4 (100–1000%), or 5 (>1000% deviation). The sum of
these values was further ranked to create a combined injury criteria that varied from no injury
(0), low injury (1 to<5), moderate injury (5-to <12) to high injury ( 12).
In vivo activity
To evaluate BNIPSpd (9) efficacy in vivo, five- to six-week-old female BALB/c mice (Charles
River) and infected with T. cruzi trypomastigotes expressing luciferase. Parasites were collected
from the supernatants of a monolayer of Vero infected cells, washed and suspended in PBS-
glucose 0.2%, and injected intraperitoneally (1 x 104 per mouse). After 7 days of infection,
mice were treated with drugs for 4 consecutive days orally with (benznidazole in 20% Kolli-
phor HS 15) or intravenously with (BNIPSpd (9) in 10% DMSO) at a dose of 100 or 5 mg/kg/
day, respectively. Infection and treatment efficiency were evaluated following subcutaneous
injection of 2.1 mg of luciferin and through live imaging using an IVIS Lumina LT (Perkin
Elmer). Images of the animals were analysed using the Living Image software (Perkin Elmer).
Pharmacokinetics
The pharmacokinetic profile of BNIPSpd was determined following intravenous injection of 5
mg/kg in BALB/c mice. The blood was collected from tail veins after 0, 5, 15, 30, 45 min, 1, 3,
24, 48 and 72 h of drug administration. Blood concentrations of the drug were analysed by
UHPLC- ESI-MS/MS.
Results
Genetic validation of TcSir2rp1
In order to evaluate the role of TcSir2rp1 in T. cruzi survival and infectivity, a genetic valida-
tion approach was taken. Multiple attempts to knockout a single allele in epimastigotes (with
various different constructs/drug selection markers) of TcSir2rp1 failed, indicating a possible
lack of mono-allelic viability and thus essentiality. As such, a non-epitope tagged ectopic copy
of the gene was successfully introduced into epimastigotes on a pTcINDEX over-expression
vector, principally to introduce an ectopic copy of the gene to T. cruzi, and thus did not require
any degree of control over the level gene expression. This was followed by successful sequential
knockout of both wild-type alleles as confirmed by PCR (S2 Fig), qRT-PCR, revealed that
introduction of the pTcINDEX increased the RNA level for TcSir2rp1 by ~30-fold compared
to wild-type. The growth and morphology of all of these genetically altered cell-lines were
indistinguishable from wild-type cells. These data strongly suggest that TcSir2rp1 is an essen-
tial gene in epimastigote T. cruzi.
TcSir2rp1 is a canonical sirtuin with NAD+-dependent deacetylase activity
Recombinant TcSir2rp1 was expressed and affinity purified as a C-terminal hexa-histidine
tagged protein. The resultant protein was shown to be pure by SDS-PAGE and of the expected
size (~40 kDa) (Fig 1A). Deacetylase activity was measured as described previously for LiSIR2rp1
[22], in a coupled reaction based on the ability of lysylendopeptidase to digest deacetylated lysine,
but not acetyllysine, residues, thereby releasing a quencher group from the molecule, allowing
the fluorophore to emit fluorescence in a time-resolved manner. Deacetylase activity was depen-
dent on NAD+ confirming TcSir2rp1 to be a NAD+-dependent deacetylase (Fig 1B).
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Furthermore, when incubated with the histone deacetylase class I and II inhibitor trichostatin A
(TSA) at 1 μM, TcSir2rp1 still displayed 77 ± 8% of activity (Fig 1B). TSA is a poor inhibitor of
sirtuins (class III deacetylases), confirming the classification of the protein as a canonical Sir2.
The steady-state kinetic parameters (Km, Vmax, kcat and kcat/Km values) of deacetylase activ-
ity were determined (Table 1). By way of confirmation, the same kinetic parameters were also
independently assessed using an electrophoretic mobility shift assay, performed as described
previously [67]. Highly similar values (Km’s of 38.7 ± 1.5 μM for NAD+ and 32.3 ± 6.0 μM for
substrate (TSPQPKK-Ac)) were obtained using the alternative microfluidic based assay con-
firming that the two different techniques generated essentially similar results when used to
assess TcSir2rp1 NAD+-dependent deacetylase activity. The kinetic data obtained for the
NAD+ cofactor is highly similar to that obtained for T. brucei Sir2rp1 whilst the substrate Km
values reported here are 2-4-fold lower [68]. When compared to yeast Sir2 and the human
SIRT2, TcSir2rp1 also displays a high deacetylation activity as demonstrated by the catalytic
efficiency (Km/kcat) constants calculated for the homologue enzymes [69, 70]. Catalytic effi-
ciencies are the most relevant constant in physiological conditions since they define the rate of
the reaction when substrate concentrations are not at saturating levels, as for most cellular
enzymatic reactions [70].
The above results were used to establish a standard screening assay (10 μM Ac-peptide and
200 μM NAD+). Nicotinamide was tested in order to evaluate if small molecules could inhibit
the enzymatic activity described. Nicotinamide is a classic non-competitive inhibitor of sir-
tuins that has been used to characterize several enzymes [22, 71]. A dose-response curve of nic-
otinamide inhibition of TcSir2rp1 indicates an IC50 of 456 ± 44 μM (Fig 1E). This value is
significantly higher when compared to the IC50 determined for other sirtuins like the human
SIRT1 (118.3 ± 23.6 μM), the Plasmodium falciparum Sir2A (51.2 ± 3.0 μM) or the LiSir2rp1
(39.4 ± 5.0 μM) previously described [46, 72]. When a concentration of 200 μM of nicotin-
amide was tested against TbSir2rp1, LiSir2rp1 and the human SIRT1, TcSir2rp1 only had a
mild inhibition of 34 ± 1%, whereas the inhibition was 70 ± 5%, 82 ± 0%, 66 ± 10% for
TbSir2rp1, LiSir2rp1 and human SIRT1, respectively (Fig 1F). Some studies have previously
reported the anti-parasitic activity of nicotinamide on T. cruzi, but, to our best knowledge, this
is the first report that proves the molecular inhibition of the parasite sirtuin by nicotinamide
[45, 73].
Fig 1. Trypanosoma cruzi Sir2rp1 characterization and inhibition by nicotinamide. A) Purity analysis of 5 and 10 μg of TcSir2rp1 by SDS-PAGE stained
with Coomassie brilliant blue (left panel). Western Blot analysis of 100 ng of the hexa-histidine tailed TcSir2rp1 recombinant protein with an anti-HisTag
antibody. B) TcSir2rp1 deacetylase activity was measured with a fluorimetric kit in the presence or absence of NAD+ (+CTRL), and in presence of 1 μM of
trichostatin A (TSA). Bars represent mean + standard deviation. Data from 3 independent experiments. C) Deacetylation reactions for the determination of
the kinetic constants of Ac-peptide. NAD+ was fixed at 2000 μM while Ac-peptide was varied (0.63 to 40 μM). Plots of initial velocities versus [Ac-peptide]
were fitted to the Michaelis-Menten equation, yielding the kinetic constants (see Table 1). D) Deacetylation reactions for the determination of the kinetic
constants of NAD+. Ac-peptide was fixed at 40 μM while NAD+ was varied (15.63 to 2000 μM). Plots of initial velocities versus [NAD+] were fitted to the
Michaelis-Menten equation, yielding the kinetic constants (see Table 1). Dots and error bars represent mean + standard deviation. C-D) Data from 3
independent experiments. E) Dose-response curve of TcSir2rp1 inhibition by nicotinamide. Data represents the average + standard deviation of three
independent experiments. F) Differential inhibition of TcSir2rp1, TbSir2rp1, LiSir2rp1 and hSIRT1 by a dose of 200 μM of nicotinamide (NAM). Bars
represent mean + standard deviation. Data from 2 independent experiments. Differences between the experimental groups were considered significant as
follows:  p<0.05,  p<0.005,  p<0.001 and  p<0.0001.
https://doi.org/10.1371/journal.pntd.0006180.g001
Table 1. Kinetic parameters determined for TcSir2rp1.
Ac-Peptide NAD+
Km (μM) 14.23 ± 0.61 38.32 ± 9.64
vmax (μM.s-1) 0.034 ± 0.003 0.018 ± 0.004
kcat (s-1) 0.136 ± 0.013 0.075 ± 0.018
kcat/Km (mM-1.s-1) 9.585 1.956
https://doi.org/10.1371/journal.pntd.0006180.t001
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Inhibitory activity of BNIP derivatives on TcSir2rp1
We next evaluated the enzymatic inhibition of TcSir2rp1 by a class of experimental com-
pounds previously characterized as inhibitors of the orthologue enzyme of L. infantum [46] as
well as the newly synthetized derivatives. BNIP derivatives are constituted by two naphthalimi-
dopropyl groups separated by a linker that varies in length and functional groups, and have
been characterized as NAD+-competitive inhibitors of LiSir2rp1 [74]. In this study, an addi-
tional set of compounds was synthetized with the objective of improving cellular target bind-
ing by including heteroatoms in the alkyl chain connecting the two naphthalimidopropyl
groups, as well as by introducing cyclic structures in the linker (Fig 2). The results are summa-
rized in Fig 3A and indicate the percentage of inhibition of the NAD+-dependent deacetylase
activity for a single dose concentration of 10 μM. Of all the compounds tested, compounds 2,
3, 8, 9, 13 and 9a had a statistically significant inhibition of the enzyme. In order to verify a
concentration dependent effect on enzymatic inhibition, compounds 2, 8, 9 and 9a were addi-
tionally tested at 50 μM, whereas compound 3 and 13 were tested at 20 μM due to low solubil-
ity. Inhibition percentages for this higher concentration were 55 ± 4%, 34 ± 11%, 31 ± 9%,
72 ± 6%, 48 ± 6 and 29 ± 4% for compounds 2, 3, 8, 9, 13 and 9a, respectively (Fig 3B). Only
compound 9 demonstrated a statistically significant dose-dependent increase in inhibition
(1-way ANOVA, p value <0.05). In fact, compound 9 was one of the most active compounds
against TcSir2rp1, with a 10 μM dose inhibiting almost 50% of the NAD+-dependent deacety-
lase activity, a concentration 45 times lower than the necessary for nicotinamide to achieve the
same level of inhibition. Compound 9 is a derivative of compound 5 by substitution of one of
the carbons in the linker chain by a nitrogen atom. Since compound 5 was not active against
the enzyme, it is possible that the substitution of the nitrogen allows the establishment of addi-
tional molecular interactions with the enzyme and/or modifies the rigidity of the linker chain
resulting in higher inhibition. Compound 9a is also a derivative from compound 5 with eight
atoms in the linker chain separating the two naphthalimidopropyl groups, but with two
oxygen atoms in substitution of two carbons. This modification also seems to increase the
inhibitory activity against TcSir2rp1 (28 ± 13%), but it is not as marked as for compound 9.
Although a clear correlation between the length of the linking chain and enzymatic inhibition
was established for the L. infantum orthologue [46], the same was not verified with TcSir2rp1.
Compounds with 5 and 6 carbons in the linker chain also displayed some inhibitory activity
against the enzyme (compound 2, 42 ± 13% and 3, 31 ± 8%, respectively), but when tested at a
higher concentration, the increase was not statistically significant. Compound 3 was only
tested at 20 μM due to poor solubility. In general, the most active inhibitors of TcSir2rp1 were
also selective towards the T. cruzi enzyme, as demonstrated by inhibition of a human sirtuin
homologue, hSIRT1. In addition to hSIRT1 inhibition previously described for compounds 1–
11 [46], compounds 12-9a were also tested at 10 μM against this enzyme (S1 Table, see sup-
porting information). Compound 6b was the most active against the human homologue
enzyme (44 ± 8% of inhibition), but was a weak inhibitor of TcSir2rp1 (8 ± 5%) at the same
concentration of 10 μM. Compound 13 also had a reduced activity against hSIRT1 (15 ± 4%),
but was a much stronger inhibitor of the T. cruzi enzyme, with an inhibition at least 3-fold
higher (50 ± 8%).
BNIPs are potent on-target in vitro inhibitors of Trypanosoma cruzi
epimastigotes
As the deacetylase activity was inhibited by some BNIP derivatives, they were also tested
against T. cruzi epimastigotes (Table 2). Some of these compounds (3, 6 and 9) showed moder-
ate activity (EC50), while compounds 7 and 2 were just as potent as nifurtimox, the positive
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control. To investigate if the BNIP derivatives’ trypanocidal activity is correlated with Sir2rp1
inhibition, compounds were also tested against the pTcINDEX overexpressing TcSir2rp1 cell-
line, described earlier. As expected the nifurtimox EC50 did not alter significantly compared to
the wild-type cell line, nor did that of compound 7. However, the EC50 values of the other 4
BNIP derivatives did increase 2.8–4.8 fold, strongly suggesting that these BNIP derivatives
Fig 2. Chemical structures of the bisnaphthalimidopropyl derivatives used in the present study. R = H in all
compounds except for compound 13.
https://doi.org/10.1371/journal.pntd.0006180.g002
Fig 3. Enzymatic inhibition of TcSir2rp1 by BNIP derivatives. A-B) The percentage of inhibition of the NAD+-dependent deacetylase activity of TcSir2rp1
by BNIP derivatives is represented in the y axis. Positive (no drug) and negative (NAM, nicotinamide at 2 mM) controls are represented. Bars represent the
average + standard deviation of at least two independent experiments. Differences between the experimental groups were considered significant as follows: 
p<0.05,  p<0.001 and  p<0.0001.
https://doi.org/10.1371/journal.pntd.0006180.g003
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were trypanocidal, because they were “on-target”, i.e. inhibiting TcSir2rp1and causing cell
death.
BNIPs are potent in vitro inhibitors of Trypanosoma cruzi intracellular
amastigotes
Once demonstrated that the deacetylase enzymatic activity is inhibited by some BNIP deriva-
tives and they are also on-target against epimastigotes, the compounds were next tested using
an in vitro HCS assay on the medically relevant intracellular form of amastigotes (S3 Fig). In
this assay, the compounds are incubated for 72 hours with cells previously infected with wild-
type trypomastigotes for 24 hours. The readout was done by comparing the average number of
amastigotes per cell that developed by the end of the incubation period. The quality of the
assay was statistically evaluated by the calculation of the z-factor [75], that represents the reli-
ability of the assay in distinguishing positive controls confidently from negative controls. Vary-
ing from 0 to 1, z-factor values higher than 0.5 are considered acceptable for drug screening.
The z-factor obtained was 0.68, validating the use of the assay (S3B Fig). The reference drug
benznidazole was assayed for quality control and showed an EC50 of 1.23 ± 0.30 μM, in accor-
dance with previous studies [76].
In order to prioritize compounds, all the BNIP derivatives were initially screened at a single
dose of 2.5 μM (Fig 4A), where all of the compounds were fully soluble. The compounds that
presented high anti-parasitic activity (>40%) and low toxicity [high cell ratio, defined as (aver-
age number of cells for the compound / average number of cell for the DMSO 0,5% control),
>70%], represented in a blue box, were selected for dose-response curve analysis. A set of
compounds that was not toxic at 2.5 μM (green box) was further tested at 10 μM. It is worth
noting that compound 2, which showed moderate inhibition of TcSir2rp1 and good on-target
trypanocidal activity against T. cruzi epimastigote cells (Table 2), failed this hurdle due to high
cytotoxicity issues (Fig 5A). Again, the compounds that had high anti-parasitic activity and
low toxicity were selected for dose-response analysis (blue box, Fig 4B). Compounds 10 and 6c
were not tested at 10 μM due to poor solubility. Compounds 1, 6, 8, 9, 12, 13, 1a, 1b, 6a, 7a
and 9a (Fig 4C and Table 3) were assayed by dose-response curves in the same conditions of
the primary screening. Compound 9, the strongest inhibitor of TcSir2rp1 and for on-target
killing of epimastigotes (Table 2), was also active against T. cruzi amastigotes, presenting an
EC50 of 2.84 ± 0.30 μM, in the range of the reference drug benznidazole (1.23 ± 0.30 μM). In
addition, it was the least toxic of the compounds analysed by dose-response curve, with a CC50
of 24.47 ± 0.45 μM, resulting in a selectivity index (SI) of 8.8 units. Compound 9a, an analogue
of 9 with two oxygen atoms in the linking chain instead of one nitrogen atom, was also active
and presented a similar EC50 of 3.43 ± 0.57 μM. However, it was less selective than compound
Table 2. EC50 values (μM) of BNIP derivatives and nifurtimox against T. cruzi epimastigotes, wild-type (WT) and cells overexpressing TcSir2rp1 (OE) with the
pTcINDEX.
Compounds WT OE Fold-increase
2—BNIPDapen 1.77 ± 0.68 7.94 ± 0.78 4.49
3—BNIPDahex 33.6 ± 1.5 102.3 ± 9.9 3.04
6—BNIPDanon 23.4 ± 2.8 112.6 ± 8.2 4.81
7—BNIPDadec 2.53 ± 0.41 2.97 ± 0.60 1.17
9—BNIPSpd 13.3 ± 0.6 36,1 ± 1.5 2.77
Nifurtimox 2.11 ± 0.15 2.24 ± 0.14 1.06
Values are means ± SD (n = 4)
https://doi.org/10.1371/journal.pntd.0006180.t002
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9 (2.1 units). Compound 5 which is also the same length between the naphthalimidopropyl
groups, but only made of methylene moieties, has very little if any activity against either the
enzyme or amastigotes. Compound 13, also an inhibitor of TcSir2rp1 (50 ± 8%), was the most
active compound against T. cruzi amastigotes, with an EC50 of 0.59 ± 0.23 μM. It was not possi-
ble to calculate the CC50 since the highest concentration tested allowed by the solubility of the
compound (2.5 μM) did not reduce the cell ratio below 50%, making the SI of the compound
at least 4.2. The second most potent hit, compound 1b, is a derivative of compound 1 where a
Fig 4. In vitro activity of BNIP derivatives. A) Primary screening of BNIP derivatives by an in vitro assay for
intracellular T. cruzi amastigotes at a single dose of 2.5 μM. Values for both anti-parasitic activity and cell ratio are
represented in the dot plot graph. The blue square represents the zone of selection for active, low toxicity hits to be
evaluated by dose-response curve analysis. The green square represents the zone of selection for compounds to be
tested at a higher dose. B) Primary screening of the compounds selected for testing at a higher dose of 10 μM. Values
for both anti-parasitic activity and cell ratio are represented in the dot plot graph. The blue square represents the zone
of selection for active, low toxicity hits to be evaluated by dose-response curve analysis. C) Representation of the
selectivity indexes of the compounds analysed by dose-response curve analysis, with the determined anti-parasitic
activity (EC50) in the y axis, and the cell ratio (CC50) in the x axis. Dots represent the average of three independent
experiments.
https://doi.org/10.1371/journal.pntd.0006180.g004
Fig 5. In vitro hepatocytes and neurons injury scores for BNIPSpd (9) by HCS. The score was calculated as the sum of individual scores obtained
from a panel of in vitro cytotoxicity assays that include: mitochondrial dysfunction measured by TMRM probe dynamics in cells; membrane integrity
assayed by lactate dehydrogenase quantification; DNA damage by imaging with H2AX antibody; apoptosis by caspase 3/7 activation; and neurite
outgrowth as imaged with an anti-tubulin III antibody. Nimesulide (400 μM), an approved drug with a mild toxicological profile, was included as a
toxicity control.
https://doi.org/10.1371/journal.pntd.0006180.g005
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cyclohexane moiety was introduced as a spacer between the naphthalimidopropyl groups. The
synthesis of this compound resulted in two isomers with a significant difference in their anti-
parasitic activity, where the trans isomer (compound 1b) presents an EC50 of 0.78 ± 0.12 μM
and the cis isomer (compound 1a) an EC50 of 6.09 ± 0.14 μM. Such a difference suggests this
particular stereoisomeric configuration improves anti-parasitic activity. Activity of nicotin-
amide in the amastigote assay was also assessed, but there was no activity detected up to a con-
centration of 2000 μM.
BNIPSpd testing in a mouse model for Chagas disease
Compound 9, BNIPSpd, showed the best enzymatic inhibition, low EC50s against epimasti-
gotes (potentially on target) and the medically relevant amastigote stages of the parasite and
some degree of selectivity. Based upon these parameters it was decided to follow up its charac-
terization. The compound toxicity was further evaluated against a panel of primary cells to
determine tissue specific toxic effects. The results of cytotoxicity against neurons, hepatocytes
and MDCK cells, and the cardiotoxicity determination by hERG predictor method are sum-
marized in Table 4.
As shown, BNIPSpd (9) presents hepatotoxicity and neurotoxicity values very similar to its
efficacy concentration (SI of 1.1 and 1.4 respectively). On the other hand, it seems not to be
nephrotoxic (SI of 35.2) or cardiotoxic (hERG channel 99.6% functional). The toxicity values
Table 3. Anti-parasitic activity, cytotoxicity and selectivity index of BNIP derivatives selected for dose-response curve analysis.
Compound Anti-T. cruzi Activity
Amastigotes μM
(EC50 ± SD)
C2C12 Cytotoxicity μM
(CC50 ± SD)
Selectivity Index
1—BNIPDabut 1.71 ± 0.23 2.91 ± 0.94 1.7
6—BNIPDanon 1.45 ± 0.37 2.35 ± 0.77 1.7
8—BNIPDadodec 1.43 ± 0.10 1.91 ± 0.06 1.3
9—BNIPSpd 2.84 ± 0.18 24.47 ± 0.45 8.8
12—BNIPDmPP 28.74 ± 4.09 > 50 > 1.7
13—BCNIPP 0.59 ± 0.23 > 2.50 > 4.2
1a - cis BNIP-1,4-Dacyhex 6.09 ± 0.14 8.74 ± 1.14 1.4
1b - trans BNIP-1,4-Dacyhex 0.78 ± 0.12 > 2.50 > 3.2
6a - BNIPDPP 1.45 ± 0.30 2.88 ± 0.12 2.0
7a - BNIPDapp 13.58 ± 2.90 19.30 ± 5.64 1.4
9a - BNIPDaoxoct 3.43 ± 0.57 7.37 ± 0.65 2.1
Benznidazole 1.23 ± 0.30 > 100 > 81.0
Selectivity Index = CC50 cell line/EC50 T. cruzi
Values are means ± SD (n = 4)
https://doi.org/10.1371/journal.pntd.0006180.t003
Table 4. Cytotoxicity and selectivity of BNIPSpd (9).
Cell type Cytotoxicity Selectivity Index
Hepatotoxicity (Hepatocytes)  3.1 μM 1.1
Neurotoxicity (Neurons)  3.9 μM 1.4
Nephotoxicity (MDCK cells)  100 μM 35.2
Cardiotoxicity (hERG predictor) 0.36 ± 0.51% -
Selectivity Index = CC50 cell line / EC50 T. cruzi
https://doi.org/10.1371/journal.pntd.0006180.t004
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are higher than the corresponding ones for the C2C12 cells (Table 3, SI of 8.8), but this is not
surprising given the fact that the primary cells are usually more sensitive. Furthermore, the
toxic effects at the cellular level were evaluated and quantified by a set of in vitro assays that
include mitochondrial dysfunction, membrane integrity, DNA damage, apoptosis and neurite
outgrowth on hepatocytes and neurons (Fig 5). This analysis could not be performed in the
MDCK cell line due to the high amounts of DMSO to test the required BNIPSpd (9) concen-
tration being toxic for these cells.
Nimesulide, an approved and widely used anti-inflammatory drug, was included at a con-
centration of 400 μM as a control of toxicity [77–79]. The results are presented in Fig 5. In
summary, BNIPSpd (9) showed a low injury score for hepatocytes, with no toxicity up to
50 μM and moderate injury score for neurons, where toxicity was most significant from
12.5 μM. These values correspond to the range within the efficacy concentration for this com-
pound (2.84 μM). Despite showing a mild injury score for neurons, it should be kept in mind
that further analysis needs to be done in order to determine whether the compound is capable
of crossing the blood-brain barrier or not. Indeed, a compound could be very neurotoxic but
never been able to reach the neurons. The main mechanisms responsible for the neurotoxicity
are the caspase 3/7 activation, a measure of apoptosis and disruption of membrane integrity as
assessed by LDH release. As the concentration of drug increases other toxicity mechanisms
like mitochondrial dysfunction and neurite outgrowth start to contribute to the overall cyto-
toxicity score. In conclusion, up to concentrations of 10 μM, BNIPSpd (9) appears to be safe
for further evaluation in an animal model for Chagas disease.
Finally, BNIPSpd (9) in vivo activity was characterized in a murine model of T. cruzi infec-
tion and using bioluminescence imaging. A bioluminescent T. cruzi Y strain (Luc+) was
obtained like previously described [47] and the in vitro limit of detection in the bioimaging
equipment IVIS Lumina LT was determined to be 104 parasites (t-test, p-value < 0.05) (S4A
Fig). Different numbers of Luc+ trypomastigotes were tested in order to assess which condition
yielded the best readout (S4B Fig). When injected intraperitoneally with 104 parasites, the
mice developed an infection at first mostly located around the inoculation site (day 7) but that
later spread to the whole body (S4B Fig). Similar observations were made for the 105 and 106
inoculates but 104 parasites yielded a higher and more reproducible increase of the whole body
bioluminescent signal.
A regimen of 5 mg/kg/day of BNIPSpd (9) was administered intravenously for 4 consecu-
tive days, while a positive control with a dose of 100 mg/kg/day of benznidazole per os and the
respective vehicle controls were also performed (S5A Fig). Unfortunately, BNIPSpd (9) did
not exhibit any in vivo activity, since bioimaging analysis demonstrates the infection pro-
gressed as in the animals treated with the vehicle only, which showed on average an increase in
the luminescence signal by 40-fold. By comparison, animals treated with benznidazole at 100
mg/kg/day displayed, on average, a 700-fold reduction in the bioluminescence signal com-
pared to mice treated with vehicle only (S5A Fig).
To investigate whether the lack of anti-parasitic activity in vivo could be due to the pharma-
cokinetics profile of BNIPSpd (9) we proceeded to quantify the compound in the blood over
time. Analysis of the snapshot pharmacokinetics profile (S5B Fig) may explain the lack of in
vivo activity of BNIPSpd (9). For the first 30 mins after intravenous injection, it never reaches
a concentration equivalent to the in vitro EC50 for T. cruzi amastigotes. The highest plasma
concentration detected is 1.70 μM at the 5 min time-point, with the compound below the level
of detection after the 3 h time-point and up to 72 h post administration (lower limit of quanti-
fication is 8.1 nM). This pharmacokinetic profile indicates that a concentration of drug able to
reach and clear parasitized tissues is not achieved in this mouse model.
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TcSir2rp1 structural model and docking with BNIP derivatives
To understand how BNIPSpd (9) could interact with TcSIR2rp1, we tried to solve the X-ray
structure of the protein. Unfortunately, despite extensive crystallization optimization attempts,
crystals with only relative low resolution limit (3.5Å) could be obtained. Nevertheless, this
allowed a preliminary TcSIR2rp1 model in complex with p53 peptide substrate to be gener-
ated. The final 3.5Å TcSir2rp1 structure (Fig 6A) shows clearly defined main chain (Cα), but
only poor density is observed for side chains in some regions, thus, these side chains were
removed.
TcSIR2rp1 global fold is, as expected, similar to other sirtuins including the human SIRT2
(S6 Fig) with a large Rossmann-fold domain (composed of 6 parallel β-strands, sandwiched
between 2 layers of α-helices) and a small Zinc binding domain. The substrate peptide p53 is
bound to the cleft between the small and the large domains (Fig 6A), the co-factor binding
loop is ordered in an open conformation similar to hsSIRT2 apo structure [48] or yeast Hst2
in complex with p53 peptide and NAD [60]. D252-I298 is missing in the TcSIR2rp1 final
model due to a lack of density, which suggests high flexibility and/or potential disorder in this
region. Nevertheless it should not impact upon our docking experiments as not involved in
active site delineation and region, located at the bottom part of the Rossmann fold domain
(diametrically opposed to Zinc ion along an axis going through p53 peptide).
Docking studies were subsequently performed with the TcSir2rp1 structure, where the p53
peptide substrate was removed and compound 9 was used as a possible ligand. Several confor-
mations of compound 9 were found in a putative ligand binding site close to the NAD binding
site (Fig 6B and 6C), all with very similar binding affinities 9 ± 0.3 kcal/mol.
To investigate if this possible interaction between compound 9 and TcSir2rp1 was specific,
several human SIRT2 structures were also subjected to similar docking studies, (S7 and S8
Figs), but they were found to have similar binding affinities to those observed for TcSir2rp1.
Likewise, the two isomers, compound 1a and 1b, which showed distinct difference in EC50
activities (6.09 and 0.78 μM respectively) were also docked with TcSir2rp1 (S9 and S10 Figs),
but they very similar binding affinities to each other.
Discussion
Sirtuins have long been proposed as interesting targets to treat parasitic diseases [80, 81], but
only recently have these proteins been characterized in T. cruzi [44, 45]. Even though the local-
ization, expression and some of the important functions of T. cruzi sirtuins have been
described, to date no biochemical characterization has been performed.
Our results demonstrate that the annotated coding sequence of TcSir2rp1 encodes for an
essential (as genetically validated here) canonical sirtuin that does not display deacetylation
activity in the absence of NAD+ and is mostly insensitive to TSA. Kinetic data obtained for
TcSir2rp1 is highly similar to the values previously described for TbSir2rp1 [67]. Despite mod-
erate differences in primary sequence (61%), a close analysis of the amino acids adjacent to the
essential histidine (H142) at the catalytic site demonstrates a 100% similarity of the four amino
acids upstream and downstream, which likely participate and/or help shape the catalytic site,
and thus may explain the similarity observed. Nonetheless, it should be noted that distant
amino acids in terms of primary structure may have an influence on substrate binding and
enzymatic activity, as demonstrated in the case of PfSir2 in which the C- and N-terminal
removal led to modifications in the enzyme kinetic constants and sensitivity to nicotinamide
[72].
An essential step in the evaluation of a drug target is the proof of druggability. Even if a
gene product is deemed essential for a given organism, if the activity or function mediated by
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this protein is not amenable to modulation by small molecule inhibitors, then it is not consid-
ered to be a good drug target. To this end, it was sought to modulate TcSir2rp1 with a classic
inhibitor of this protein family, nicotinamide [82]. The enzymatic activity described was
indeed inhibited by nicotinamide, although in concentrations higher than those previously
reported for other members of the family. In particular, the IC50 for LiSir2rp1 and hSIRT1 is
11 and 4-fold lower, respectively, than the one reported here for TcSir2rp1 [46]. Another
observation that supports the resistance to nicotinamide is the fact that even when 2 mM of
NAD+ is used in reactions for the determination of the kinetic constants for NAD+, there is no
decrease in enzymatic activity unlike previously reported for other enzymes [22]. Such inhibi-
tion might be expected since nicotinamide is an endogenous product of the deacetylation reac-
tion. Nicotinamide binds to a distinct C pocket that appears to be conserved among the
sirtuins that have been structurally elucidated by co-crystallography [71]. The study of the
presence and conservation of this pocket in TcSir2rp1 may shed some light on the observed
nicotinamide resistance. Although nicotinamide has some anti-parasitic activity against Plas-
modium [83], Leishmania [84], T. brucei [85] and also T. cruzi [73], no confirmation of a sir-
tuin-mediated mechanism has been clearly established to date. In this study, no amastigote
anti-parasitic activity was detected for nicotinamide in concentrations up to 2 mM.
The search for additional inhibitors led to the identification of some BNIP derivatives as
stronger inhibitors of TcSir2rp1. This class of compounds was previously described to be
active at 10 μM, with few exceptions, against LiSir2rp1 [74]. However, no correlation has been
established between the most active compounds for L. infantum and T. cruzi enzymes, suggest-
ing that both enzymes might be targeted differentially by some of the derivatives [46]. In con-
trast to LiSir2rp1 inhibition, no structure-activity relationship regarding the length of the alkyl
chain linking the two naphthalimidopropyl groups was observed for TcSir2rp1 [75]. Although
a linker of eight carbons had no activity at 10 μM (compound 5), when some of the carbons
are substituted by heteroatoms like nitrogen (compound 9) and oxygen (compound 9a), the
activity towards TcSir2rp1 increased significantly, suggesting that the rigidity of certain con-
formations and/or the ability to establish additional molecular interactions in this part of the
molecule, increase inhibitory activity.
More importantly, some enzymatic inhibitors also demonstrated a strong anti-parasitic
activity against T. cruzi epimastigotes, which for some was shown to be on-target, due to the
increase in EC50 for the overexpressing cell-line. Moreover, amastigotes, the clinically relevant
form responsible for infection persistence in humans, were shown to be sensitive to some of
the BNIP derivatives. Differences observed between the enzymatic inhibition and the activity
in the parasite may be due to distinct interactions between BNIPs and TcSir2rp1, and/or, pos-
sibly, by the contribution of a multi-target mechanism as well as the relative efficacy of entry
into the host cell and then into the parasitophorous vacuole.
The majority of the compounds demonstrated low selectivity for the parasite and toxicity
for host cells, as indicated by their selectivity indexes. A possible explanation is the characteris-
tic DNA intercalation of BNIP derivatives that were originally developed as anti-cancer agents
[86, 87]. While this might explain some of the toxic effects observed for host cells, it should not
be excluded that DNA intercalation may be contributing to their reported anti-parasitic activ-
ity, especially since trypanosomes are susceptible to intercalating agents [88]. Analysis of
Fig 6. TcSir2rp1 structural model and docking with compound 9. A) The 3.5 Å structural model shows a large Rossmann-fold domain
(composed of 6 parallel β-strands, sandwiched between 2 layers of α-helices), and a small zinc binding domain. The substrate acetylated
peptide p53 is bound to the cleft between the small and the large domains. B-C) The substrate p53 peptide was removed from the
structure and docking studies conducted with compound 9. Several conformations (only 2 shown here) of compound 9 were possible in
a putative ligand binding site close to the NAD binding site.
https://doi.org/10.1371/journal.pntd.0006180.g006
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TcSir2rp1 by Wregex and cNLS Mapper, bio-computational tools that identify nuclear export
signals (NES) and nuclear localization signals (NLS), respectively, indicate the presence of non-
canonical NES/NLS in the sequence of this sirtuin [89, 90]. Whether TcSir2rp1 does shuttle to
and from the nucleus during specific times of the T. cruzi cell cycle, possibly to perform DNA
damage repair like the T. brucei orthologue, remains to be reported. [42], In fact, if TcSir2rp1
also has a role in DNA repair both sirtuin inhibition and DNA intercalation may be synergisti-
cally contributing to the anti-parasitic activity. Activity towards other molecular targets should
also not be excluded, especially considering that T. cruzi has another sirtuin, TcSir2rp3, that has
also been described as having important functions in different cellular processes like metacyclo-
genesis, epimastigote growth and host-cell infectivity and replication [44, 45].
The docking studies also suggests that compound 9 is unable to distinguish between
TcSir2rp1 and human SIRT2 proteins and is able to bind in multiple conformations either in
the presence or absence of p53 substrate. This is likely due to the intrinsic hydrophobicity of
sirtuin proteins and the hydrophobic nature of the two bisnapthalmidopropyl-moieties and
the highly flexible linker between them in the BNIP derivatives.
Since BNIPSpd (9) met some of the biological criteria recommended for T. cruzi drug dis-
covery follow-up, it was decided to further evaluate it as a possible lead compound [91]. The
toxicity determination showed that although it has low SI values (around 1 for hepatocytes and
neurons), the toxicity values in the μM range could be considered a promising starting point
for further optimization. Moreover, the cardiotoxicity evaluation showed that cardiomyocyte
function does not seem to be compromised. On the other hand, a more in-depth analysis of
the toxicity by HCS showed that there is very limited injury to hepatocytes and neurons.
BNIPSpd (9) showed no hepatotoxicity up to 12.5 μM. At 50 μM there is a low injury score
mainly due to caspase 3/7 activation (although the viability -WST8- is also altered). In regard
to neurotoxicity, as expected, the neurons start to suffer toxicity at lower concentrations; neu-
rons showed no effects up to 0.7 μM but the injury score starts to rise in a dose dependent
manner up to 12.5 μM. At higher concentrations (50 μM) the injury score is maintained at
high levels. The mechanism of toxicity in neurons and hepatocytes seems to be the same, as
the main parameter was caspase 3/7 activation followed by membrane integrity. At higher con-
centrations, all the parameters tested were affected. More assays need to be performed to evalu-
ate the capacity of BNIPSpd (9) to cross the blood-brain barrier. In addition, BNIPSpd (9)
showed decent aqueous solubility (up to 70%) and gastric stability (100%).
Assessment of efficacy of BNIPSpd (9) in mice infected with bioluminescent T. cruzi para-
sites by live imaging revealed lack of in vivo activity. The results may be explained by the phar-
macokinetic profile of the compound, whose concentration in the blood always remained
below the in vitro EC50 for amastigotes. The compound was no longer detected 3 hours after
administration, even though the drug is administered by intravenous injection, the most bio-
available route. An explanation is that most of the compound is rapidly metabolized in the
organism to an inactive form or removed from circulation. Medicinal chemistry modifications
of the compound, as well as alternative formulations may improve activity and pharmacoki-
netics in the host organism.
Supporting information
S1 Supporting Information.
(DOCX)
S1 Fig. Schematic representation of the synthesis of compounds. cis BNIP-1,4-Dacyhex
(1a), trans BNIP-1,4-Dacyhex (1b) and BNIP-1,4-Babenz (1c).
(TIF)
Inhibitors of TcSir2rp1 for Chagas disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006180 January 22, 2018 23 / 30
S2 Fig. Validation of the epimastigote T. cruzi TcSir2rp1-modified cell lines by colony
PCR. PCR validation of the genetically manipulated cell-lines: Lane 1: WT; Lane 2: over-
expressing cell-line pTcINDEX TcSir2rp1: Hyg; Lane 3: over-expressing and single knockout
cell-line TcSir2rp1ΔTcSir2rp::Pac pTcINDEX TcSir2rp1: Hyg; Lane 4: over-expressing and
double knockout cell-line TcSir2rp1ΔTcSir2rp::Pac, Bsd pTcINDEX TcSir2rp1: Hyg. Primers
used for ORF only are the TcSir2rp1 ORF forward and reverse primers, expected PCR product
1092bp. Primers used for the 5’UTR+ORF are the 5’ UTR F1 and TcSir2rp1 reverse ORF,
expected size 1683bp.
Forward and reverse primers used for hygromycin resistance cassette (HYG), expected size
1041bp. Forward and reverse primers used for puromycin resistance cassette (PAC), expected
size 610bp. Forward and reverse primers used for blasticidin resistance cassette (BSD),
expected size 432bp. Forward and reverse ORF primers (5’-TATGCGGCCGCATGAATCAA
GATAACGCCAAC-3’ and 5’- TATGGATCCTTATTTTCGGTCTGTCTGTGTGTACAT
G-3’ respectively. 5’ and 3’ UTR Primers respectively (F1: 5’-TATGCGGCCGCAGGAACCC
ACCACTTC-3’; R1: 5’- CGTTTAAACTTACGGACCGTCAAGCTTTGGGAAGAAGTAATC
CACCT-3’; F2: 5’-GACGGTCCGTAAGTTTAAACGGGATCCACCGAAAATAAGAGGA-3’;
R2: 5’-TATGCGGCCGCGATGCTCTTCATATTTATCTTGC-3’.
(TIF)
S3 Fig. Development of the high-content screening assay against intracellular amastigotes
of Trypanosoma cruzi. A) Representative images of the control conditions used in the assay:
infected cells, non-infected cells and infected cells treated with 100 μM of benznidazole (BZN).
B) Statistical validation of the screening assay based on the readout of parasites per cell, with a
Z value of 0.68. C) Dose-response curve against the reference drug benznidazole, demonstrat-
ing and EC50 in line with previously published values [62].
(TIF)
S4 Fig. Setting the T. cruzi infection in mice. A) In vitro detection limit of Luc+ trypomasti-
gotes in a 96-well plate incubated with luciferin and imaged using the IVIS LUMINA LT. Cir-
cles and vertical lines represent the average ± standard deviation of the average radiance of
quadruplicates. Statistical analysis was performed by standard t-test relative to luciferin back-
ground with no parasites. Significance is shown in asterisks (, p-value 0.05). B) Comparison
of different inocula of Luc+ trypomastigotes (104, 105, 106) tested in BALB/c mice infections by
quantification of the signal over 5 minutes (average radiance, photons/sec/cm2/sr) C) Repre-
sentative images of the anesthetized bio-imaged mice infected with 104 trypomastigotes at the
time points before and after treatment (day 7 and 11 after infection, respectively).
(TIF)
S5 Fig. In vivo efficacy testing of BNIPSpd (9). A) Mice were infected with 104 Luc+ trypo-
mastigotes by intraperitoneal injection. Treatments (BZN, benznidazole at 100 mg/kg/day per
os, and BNIPSpd (9) at 5 mg/kg/day by intravenous injection) were initiated 7 days after infec-
tion, as well as the respective controls (KP, Kolliphor HS 15 20% per os and DMSO 10% by
intravenous injection). Imaging was performed before treatment, at 7 days post-infection and
after treatment, at 11 days post-infection, using an IVIS LUMINA LT and upon injection of
2.1 mg luciferin. In the lower panel, bioluminescence signal of whole mice represented in aver-
age radiance (photons/sec/cm2/sr) quantified before and after treatment. Data representative
of two independent experiments. B) Snapshot Pharmacokinetics of BNIPSpd (9) in BALB/c
mice by quantification of BNIPSpd (9) in the blood of mice by UHPLC-MS/MS ESI+ at differ-
ent time-points after administration of a 5 mg/kg dose by intravenous injection. Data is the
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average of two independent experiments. The dashed line represents the value of EC50 for
BNIPSpd (9) in the in vitro assay against T. cruzi amastigotes, and the dotted line represents
the lower limit of quantification of the technique.
(TIF)
S6 Fig. Superimposed structures of TcSir2rp1 and Human SIRT2. TcSir2rp1 structure in
green, with p53 peptide carbons in pale blue. Human SIRT2 (4rmj) structure in purple, with
carbons of ligands ADP and nicotinamide in pale pink.
(TIFF)
S7 Fig. Docking of Human SIRT2 (apo structure 3zgo) with compound 9. A) image shows
the same orientation as TcSir2rp1 with compound 9 (Fig 6B and 6C), B) is the same model
rotated by 90˚ to view putative ligand binding pocket, with a zoomed in image on compound
9. C) images showing an alternative mode of compound 9 binding.All of these have similar
binding affinities to those observed for TcSir2rp1.
(TIFF)
S8 Fig. Docking of Human SIRT2 (4rmj after removing ligands) with compound 9. A)
image shows the same orientation of TcSir2rp1 with compound 9 (Fig 6B and 6C), B) is same
model rotated 90˚. C) is the same model turned by an additional 90˚. D) is the same rotation
as C, but with an alternative binding mode by compound 9, which is zoomed in on compound
9 (E). All of these have similar binding affinities to those observed for TcSir2rp1.
(TIFF)
S9 Fig. TcSir2rp1 structure and docking with compound 1a. A) image shows the same ori-
entation of TcSir2rp1 with compound 9 (Fig 6B and 6C), but with 1a docked, which is zoomed
in on (B), and with an alternative binding orientation (C). D) Shows TcSir2rp1 in the presence
of p53 and docked compound 1a, which is zoomed in on (E), and with an alternative binding
orientation (F). These all have very similar binding affinities 8–11 kcal/mol.
(TIFF)
S10 Fig. TcSir2rp1 structure and docking with compound 1b. A) image shows the same ori-
entation of TcSir2rp1 with compound 9 (Fig 6B and 6C), but with 1b docked, which is zoomed
in on (B), and with an alternative binding orientation (C). D) Shows TcSir2rp1 in the presence
of p53 and docked compound 1a, which is zoomed in on (E), and with an alternative binding
orientation (F). These all have very similar binding affinities 8–11 kcal/mol.
(TIFF)
Acknowledgments
We thank Paola Minoprio and Sophie Goyard at Institut Pasteur in Paris for providing
pTREX-luc used to generate the T. cruzi Y Luc+ strain.
Author Contributions
Data curation: Ce´line Ronin.
Formal analysis: Ross P. Coron.
Funding acquisition: Iain K. Pemberton, Jane MacDougall.
Investigation: Luı´s Gaspar, Ross P. Coron, Paul KongThoo Lin, David M. Costa, Begoña
Perez-Cabezas, Joana Tavares, Meritxell Roura-Ferrer, Isbaal Ramos, Ce´line Ronin, Louise
L. Major, Fabrice Ciesielski, Terry K. Smith, Anabela Cordeiro-da-Silva.
Inhibitors of TcSir2rp1 for Chagas disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006180 January 22, 2018 25 / 30
Project administration: Iain K. Pemberton, Jane MacDougall.
Supervision: Paola Ciapetti, Terry K. Smith, Anabela Cordeiro-da-Silva.
Writing – original draft: Anabela Cordeiro-da-Silva.
Writing – review & editing: Ce´line Ronin, Louise L. Major, Terry K. Smith, Anabela Cor-
deiro-da-Silva.
References
1. WHO Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epi-
demiol Rec, 2015, 90(6), 33–43. PMID: 25671846
2. Mathers C. D.; Ezzati M.; Lopez A. D. Measuring the burden of neglected tropical diseases: the global
burden of disease framework. PLoS Negl Trop Dis, 2007, 1(2), e114. https://doi.org/10.1371/journal.
pntd.0000114 PMID: 18060077
3. Lee B. Y.; Bacon K. M.; Bottazzi M. E.; Hotez P. J. Global economic burden of Chagas disease: a
computational simulation model. Lancet Infect Dis, 2013, 13(4), 342–348. https://doi.org/10.1016/
S1473-3099(13)70002-1 PMID: 23395248
4. Garcia MN, Woc-Colburn L, Aguilar D, Hotez PJ, Murray KO (2015) Historical Perspectives on the Epi-
demiology of Human Chagas Disease in Texas and Recommendations for Enhanced Understanding of
Clinical Chagas Disease in the Southern United States. PLoS Negl Trop Dis 9(11): e0003981. https://
doi.org/10.1371/journal.pntd.0003981 PMID: 26540273
5. Bern C. Chagas’ Disease. N Engl J Med, 2015, 373(5), 456–466. https://doi.org/10.1056/
NEJMra1410150 PMID: 26222561
6. Rassi A.; Marin-Neto J. Chagas disease. The Lancet, 2010, 375(9723), 1388–1402.
7. WHO Reporte sobre la enfermedade de Chagas. Available at: http://whqlibdoc.who.int/hq/2007/TDR_
SWG_09_spa.pdf (Accessed May 22, 2015).
8. Schmunis G. A.; Yadon Z. E. Chagas disease: a Latin American health problem becoming a world
health problem. Acta Trop, 2010, 115(1–2), 14–21. https://doi.org/10.1016/j.actatropica.2009.11.003
PMID: 19932071
9. Viotti R.; Vigliano C.; Lococo B.; Alvarez M. G.; Petti M.; Bertocchi G.; Armenti A. Side effects of benzni-
dazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther, 2009, 7
(2), 157–163. https://doi.org/10.1586/14787210.7.2.157 PMID: 19254164
10. Castro J. A.; de Mecca M. M.; Bartel L. C. Toxic side effects of drugs used to treat Chagas’ disease
(American trypanosomiasis). Hum Exp Toxicol, 2006, 25(8), 471–479. https://doi.org/10.1191/
0960327106het653oa PMID: 16937919
11. Clayton J. Chagas disease: pushing through the pipeline. Nature, 2010, 465(7301), S12–S15. https://
doi.org/10.1038/nature09224 PMID: 20571548
12. Molina I.; Gomez i Prat J.; Salvador F.; Trevino B.; Sulleiro E.; Serre N.; Pou D.; Roure S.; Cabezos J.;
Valerio L.; Blanco-Grau A.; Sanchez-Montalva A.; Vidal X.; Pahissa A. Randomized trial of posacona-
zole and benznidazole for chronic Chagas’ disease. N Engl J Med, 2014, 370(20), 1899–1908. https://
doi.org/10.1056/NEJMoa1313122 PMID: 24827034
13. Morillo C. A.; Marin-Neto J. A.; Avezum A.; Sosa-Estani S.; Rassi A. Jr.; Rosas F.; Villena E.; Quiroz R.;
Bonilla R.; Britto C.; Guhl F.; Velazquez E.; Bonilla L.; Meeks B.; Rao-Melacini P.; Pogue J.; Mattos A.;
Lazdins J.; Rassi A.; Connolly S. J.; Yusuf S.; Investigators B. Randomized Trial of Benznidazole for
Chronic Chagas’ Cardiomyopathy. N Engl J Med, 2015, 373(14), 1295–1306. https://doi.org/10.1056/
NEJMoa1507574 PMID: 26323937
14. DNDi, Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New
Evidence for Improved Therapy. Washington D.C., 2013.
15. Frye R. A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys
Res Commun, 2000, 273(2), 793–798. https://doi.org/10.1006/bbrc.2000.3000 PMID: 10873683
16. Costantini S.; Sharma A.; Raucci R.; Costantini M.; Autiero I.; Colonna G. Genealogy of an ancient pro-
tein family: the Sirtuins, a family of disordered members. BMC Evol Biol, 2013, 13, 60. https://doi.org/
10.1186/1471-2148-13-60 PMID: 23497088
17. Denu J. M. Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent dea-
cetylases. Trends Biochem Sci, 2003, 28(1), 41–48. PMID: 12517451
Inhibitors of TcSir2rp1 for Chagas disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006180 January 22, 2018 26 / 30
18. Liou G. G.; Tanny J. C.; Kruger R. G.; Walz T.; Moazed D. Assembly of the SIR complex and its regula-
tion by O-acetyl-ADP-ribose, a product of NAD-dependent histone deacetylation. Cell, 2005, 121(4),
515–527. https://doi.org/10.1016/j.cell.2005.03.035 PMID: 15907466
19. Haigis M. C.; Mostoslavsky R.; Haigis K. M.; Fahie K.; Christodoulou D. C.; Murphy A. J.; Valenzuela D.
M.; Yancopoulos G. D.; Karow M.; Blander G.; Wolberger C.; Prolla T. A.; Weindruch R.; Alt F. W.;
Guarente L. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in
pancreatic beta cells. Cell, 2006, 126(5), 941–954. https://doi.org/10.1016/j.cell.2006.06.057 PMID:
16959573
20. Liszt G.; Ford E.; Kurtev M.; Guarente L. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransfer-
ase. J Biol Chem, 2005, 280(22), 21313–21320. https://doi.org/10.1074/jbc.M413296200 PMID:
15795229
21. Garcia-Salcedo J. A.; Gijon P.; Nolan D. P.; Tebabi P.; Pays E. A chromosomal SIR2 homologue with
both histone NAD-dependent ADP-ribosyltransferase and deacetylase activities is involved in DNA
repair in Trypanosoma brucei. EMBO J, 2003, 22(21), 5851–5862. https://doi.org/10.1093/emboj/
cdg553 PMID: 14592982
22. Tavares J.; Ouaissi A.; Santarem N.; Sereno D.; Vergnes B.; Sampaio P.; Cordeiro-da-Silva A. The
Leishmania infantum cytosolic SIR2-related protein 1 (LiSIR2RP1) is an NAD+ -dependent deacetylase
and ADP-ribosyltransferase. Biochem J, 2008, 415(3), 377–386. https://doi.org/10.1042/BJ20080666
PMID: 18598238
23. Tanner K. G.; Landry J.; Sternglanz R.; Denu J. M. Silent information regulator 2 family of NAD- depen-
dent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad
Sci U S A, 2000, 97(26), 14178–14182. https://doi.org/10.1073/pnas.250422697 PMID: 11106374
24. Du J.; Zhou Y.; Su X.; Yu J. J.; Khan S.; Jiang H.; Kim J.; Woo J.; Kim J. H.; Choi B. H.; He B.; Chen W.;
Zhang S.; Cerione R. A.; Auwerx J.; Hao Q.; Lin H. Sirt5 is a NAD-dependent protein lysine demalony-
lase and desuccinylase. Science, 2011, 334(6057), 806–809. https://doi.org/10.1126/science.1207861
PMID: 22076378
25. Tan M.; Peng C.; Anderson K. A.; Chhoy P.; Xie Z.; Dai L.; Park J.; Chen Y.; Huang H.; Zhang Y.; Ro J.;
Wagner G. R.; Green M. F.; Madsen A. S.; Schmiesing J.; Peterson B. S.; Xu G.; Ilkayeva O. R.; Muehl-
bauer M. J.; Braulke T.; Muhlhausen C.; Backos D. S.; Olsen C. A.; McGuire P. J.; Pletcher S. D.; Lom-
bard D. B.; Hirschey M. D.; Zhao Y. Lysine glutarylation is a protein posttranslational modification
regulated by SIRT5. Cell Metab, 2014, 19(4), 605–617. https://doi.org/10.1016/j.cmet.2014.03.014
PMID: 24703693
26. Jeong S. M.; Haigis M. C. Sirtuins in Cancer: a Balancing Act between Genome Stability and Metabo-
lism. Mol Cells, 2015, 38(9), 750–758. https://doi.org/10.14348/molcells.2015.0167 PMID: 26420294
27. Gomes P.; Fleming Outeiro T.; Cavadas C. Emerging Role of Sirtuin 2 in the Regulation of Mammalian
Metabolism. Trends Pharmacol Sci, 2015.
28. Watroba M.; Szukiewicz D. The role of sirtuins in aging and age-related diseases. Adv Med Sci, 2015,
61(1), 52–62. https://doi.org/10.1016/j.advms.2015.09.003 PMID: 26521204
29. Mostoslavsky R.; Esteller M.; Vaquero A. At the crossroad of lifespan, calorie restriction, chromatin and
disease: meeting on sirtuins. Cell Cycle, 2010, 9(10), 1907–1912. https://doi.org/10.4161/cc.9.10.
11481 PMID: 20458180
30. Seto E.; Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb
Perspect Biol, 2014, 6(4), a018713. https://doi.org/10.1101/cshperspect.a018713 PMID: 24691964
31. Michishita E.; Park J. Y.; Burneskis J. M.; Barrett J. C.; Horikawa I. Evolutionarily conserved and non-
conserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell, 2005, 16(10),
4623–4635. https://doi.org/10.1091/mbc.E05-01-0033 PMID: 16079181
32. Muth V.; Nadaud S.; Grummt I.; Voit R. Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates RNA
polymerase I transcription. EMBO J, 2001, 20(6), 1353–1362. https://doi.org/10.1093/emboj/20.6.1353
PMID: 11250901
33. Mao Z.; Tian X.; Van Meter M.; Ke Z.; Gorbunova V.; Seluanov A. Sirtuin 6 (SIRT6) rescues the decline
of homologous recombination repair during replicative senescence. Proc Natl Acad Sci U S A, 2012,
109(29), 11800–11805. https://doi.org/10.1073/pnas.1200583109 PMID: 22753495
34. Mao Z.; Hine C.; Tian X.; Van Meter M.; Au M.; Vaidya A.; Seluanov A.; Gorbunova V. SIRT6 promotes
DNA repair under stress by activating PARP1. Science, 2011, 332(6036), 1443–1446. https://doi.org/
10.1126/science.1202723 PMID: 21680843
35. Karim M. F.; Yoshizawa T.; Sato Y.; Sawa T.; Tomizawa K.; Akaike T.; Yamagata K. Inhibition of
H3K18 deacetylation of Sirt7 by Myb-binding protein 1a (Mybbp1a). Biochem Biophys Res Commun,
2013, 441(1), 157–163. https://doi.org/10.1016/j.bbrc.2013.10.020 PMID: 24134843
36. Tsai Y. C.; Greco T. M.; Boonmee A.; Miteva Y.; Cristea I. M. Functional proteomics establishes the
interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA
Inhibitors of TcSir2rp1 for Chagas disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006180 January 22, 2018 27 / 30
polymerase I transcription. Mol Cell Proteomics, 2012, 11(5), 60–76. https://doi.org/10.1074/mcp.
A111.015156 PMID: 22586326
37. North B. J.; Verdin E. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis.
PLoS One, 2007, 2(8), e784. https://doi.org/10.1371/journal.pone.0000784 PMID: 17726514
38. Hirschey M. D.; Shimazu T.; Goetzman E.; Jing E.; Schwer B.; Lombard D. B.; Grueter C. A.; Harris C.;
Biddinger S.; Ilkayeva O. R.; Stevens R. D.; Li Y.; Saha A. K.; Ruderman N. B.; Bain J. R.; Newgard C.
B.; Farese R. V. Jr.; Alt F. W.; Kahn C. R.; Verdin E. SIRT3 regulates mitochondrial fatty-acid oxidation
by reversible enzyme deacetylation. Nature, 2010, 464(7285), 121–125. https://doi.org/10.1038/
nature08778 PMID: 20203611
39. Nakagawa T.; Lomb D. J.; Haigis M. C.; Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthe-
tase 1 and regulates the urea cycle. Cell, 2009, 137(3), 560–570. https://doi.org/10.1016/j.cell.2009.02.
026 PMID: 19410549
40. Freitas-Junior L. H.; Hernandez-Rivas R.; Ralph S. A.; Montiel-Condado D.; Ruvalcaba-Salazar O. K.;
Rojas-Meza A. P.; Mancio-Silva L.; Leal-Silvestre R. J.; Gontijo A. M.; Shorte S.; Scherf A. Telomeric
heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic
variation genes in malaria parasites. Cell, 2005, 121(1), 25–36. https://doi.org/10.1016/j.cell.2005.01.
037 PMID: 15820676
41. Tonkin C. J.; Carret C. K.; Duraisingh M. T.; Voss T. S.; Ralph S. A.; Hommel M.; Duffy M. F.; Silva L.
M.; Scherf A.; Ivens A.; Speed T. P.; Beeson J. G.; Cowman A. F. Sir2 paralogues cooperate to regulate
virulence genes and antigenic variation in Plasmodium falciparum. PLoS Biol, 2009, 7(4), e84. https://
doi.org/10.1371/journal.pbio.1000084 PMID: 19402747
42. Alsford S.; Kawahara T.; Isamah C.; Horn D. A sirtuin in the African trypanosome is involved in both
DNA repair and telomeric gene silencing but is not required for antigenic variation. Mol Microbiol, 2007,
63(3), 724–736. https://doi.org/10.1111/j.1365-2958.2006.05553.x PMID: 17214740
43. Vergnes B.; Sereno D.; Tavares J.; Cordeiro-da-Silva A.; Vanhille L.; Madjidian-Sereno N.; Depoix D.;
Monte-Alegre A.; Ouaissi A. Targeted disruption of cytosolic SIR2 deacetylase discloses its essential
role in Leishmania survival and proliferation. Gene, 2005, 363, 85–96. https://doi.org/10.1016/j.gene.
2005.06.047 PMID: 16236469
44. Moretti N. S.; Augusto L. D.; Clemente T. M.; Antunes R. P.; Yoshida N.; Torrecilhas A. C.; Cano M. I.;
Schenkman S. Characterization of Trypanosoma cruzi sirtuins as possible drug targets for Chagas Dis-
ease. Antimicrob Agents Chemother, 2015, 59(8), 4669–79. https://doi.org/10.1128/AAC.04694-14
PMID: 26014945
45. Ritagliati C.; Alonso V. L.; Manarin R.; Cribb P.; Serra E. C. Overexpression of cytoplasmic TcSIR2RP1
and mitochondrial TcSIR2RP3 impacts on Trypanosoma cruzi growth and cell invasion. PLoS Negl
Trop Dis, 2015, 9(4), e0003725. https://doi.org/10.1371/journal.pntd.0003725 PMID: 25875650
46. Tavares J.; Ouaissi A.; Kong Thoo Lin P.; Loureiro I.; Kaur S.; Roy N.; Cordeiro-da-Silva A. Bisnaphtha-
limidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. ChemMedChem, 2010, 5
(1), 140–147. https://doi.org/10.1002/cmdc.200900367 PMID: 19937668
47. Andriani G.; Chessler A. D.; Courtemanche G.; Burleigh B. A.; Rodriguez A. Activity in vivo of anti-Try-
panosoma cruzi compounds selected from a high throughput screening. PLoS Negl Trop Dis, 2011, 5
(8), e1298. https://doi.org/10.1371/journal.pntd.0001298 PMID: 21912715
48. Vazquez M. P.; Levin M. J. Functional analysis of the intergenic regions of TcP2beta gene loci allowed
the construction of an improved Trypanosoma cruzi expression vector. Gene, 1999, 239(2), 217–225.
PMID: 10548722
49. Taylor M. C. & Kelly J. M. pTcINDEX: a stable tetracycline-regulated expression vector for Trypano-
soma cruzi BMC biotechnology, 6, 32. https://doi.org/10.1186/1472-6750-6-32 PMID: 16824206
50. Grac¸a NAG, Gaspar L, Costa DM, Loureiro I, Thoo-Lin PK, Ramos I, Roura M, Pruvost A, Pemberton
IK, Loukil H, Macdougall J, Tavares J, Cordeiro-da-Silva A. 2016. Activity of bisnaphthalimidopropyl
derivatives against Trypanosoma brucei. Antimicrob Agents Chemother 60:2532–2536. https://doi.org/
10.1128/AAC.02490-15 PMID: 26787703
51. Lin P. K.; Pavlov V. A. The synthesis and in vitro cytotoxic studies of novel bis-naphthalimidopropyl poly-
amine derivatives. Bioorg Med Chem Lett, 2000, 10(14), 1609–1612. PMID: 10915063
52. Barron G. A.; Bermano G.; Gordon A.; Kong Thoo Lin P. Synthesis, cytotoxicity and DNA-binding of
novel bisnaphthalimidopropyl derivatives in breast cancer MDA-MB-231 cells. Eur J Med Chem, 2010,
45(4), 1430–1437. https://doi.org/10.1016/j.ejmech.2009.12.047 PMID: 20064676
53. Lima T., Barron R.; A., Grabowska G.; A., Bermano J., Kaur G., Roy S., Helena Vasconcelos N., K.T M.
Lin P. Cytotoxicity and Cell Death Mechanisms Induced by a Novel Bisnaphthalimidopropyl Derivative
against the NCI-H460 non-small Lung Cancer Cell Line. Anti-Cancer Agents in Medicinal Chemistry,
2013, 13(3), 414–421. PMID: 23092269
54. Kabsch W. XDS. Acta Crystallographica. Section D Biological Crystallography. 2010; 66(Pt 2): 25–132
Inhibitors of TcSir2rp1 for Chagas disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006180 January 22, 2018 28 / 30
55. Winn M.D.; Ballard C.C.; Cowtan K.D.; Dodson E.J.; Emsley P.; Evans P.R.; Keegan R.M.; Krissinel E.
B.; Leslie A.G.; McCoy A.; McNicholas S.J.; Murshudov G.N.; Pannu N.S.; Potterton E.A.; Powell H.R.;
Read R.J.; Vagin A.; Wilson K.S. Overview of the CCP4 suite and current developments. Acta Crystallo-
graphica. Section D Biological Crystallography. 2011; 67 (Pt 4):235–242
56. Keegan R.M.; Winn M.D. Automated search-model discovery and preparation for structure solution by
molecular replacement. Acta Crystallographica. Section D Biological Crystallography. 2007; 63 (Pt
4):447–457.
57. Emsley P.; Lohkamp B.; Scott W. G.; Cowtan K. Features and development of Coot. Acta Crystallogra-
phica. Section D Biological Crystallography. 2010; 66 (Pt 4), 486–501
58. Murshudov G.N.; Skubak P.; Lebedev A.A.; Pannu N.S.; Steiner R.A.; Nicholls R.A.; Winn M.D.; Long
F.; Vagin A.A. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogra-
phica. Section D Biological Crystallography. 2011 67 (Pt 4): 355–367.
59. Berman H. M., Westbrook J., Feng Z., Gilliland G., Bhat T. N., Weissig H., Shindyalov I. N., Bourne P.
E. (2000) The Protein Data Bank. Nucleic Acids Res, 28 (1): 235–242. PMID: 10592235
60. Zhao K.; Harshaw R.; Chai X.; Marmorstein R. Structural basis for nicotinamide cleavage and ADP-
ribose transfer by NAD(+)-dependent Sir2 histone/protein deacetylases. Proc Natl Acad Sci U S A.
2004 101(23):8563–8. https://doi.org/10.1073/pnas.0401057101 PMID: 15150415
61. Moniot S, Schutkowski M, Steegborn C. (2013) Crystal structure analysis of human Sirt2 and its ADP-
ribose complex. J Struct Biol., 182(2):136–43 https://doi.org/10.1016/j.jsb.2013.02.012 PMID:
23454361
62. Rumpf T., Schiedel M., Karaman B., Roessler C., North B. J., Lehotzky A., Ola´h J., Ladwein K. I.,
Schmidtkunz K., Gajer M., Pannek M., Steegborn C., Sinclair D. A., Gerhardt S., Ova´di J., Schutkowski
M., Sippl W., Einsle O., Jung M. (2015) Selective Sirt2 inhibition by ligand-induced rearrangement of the
active site. Nat Commun., 6:6263 https://doi.org/10.1038/ncomms7263 PMID: 25672491
63. Morris G. M., Huey R., Lindstrom W., Sanner M. F., Belew R. K., Goodsell D. S. and Olson A. J. (2009)
Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Computational
Chemistry, 16: 2785–91
64. Trott O., and Olson A. J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a
new scoring function, efficient optimization and multithreading, J. Computational Chemistry, 31: 455–
461
65. Schro¨dinger, The PyMOL Molecular Graphics System, Version 1.5.0.4 Schro¨dinger, LLC.
66. van Meerloo J.; Kaspers G. L.; Cloos J. Cell Sensitivity Assays: The MTT Assay. In: Cancer Cell Cul-
ture; Cree I. A., Ed. Humana Press: 2011; Vol. 731, pp. 237–245.
67. Kronenwerth M., Dauth C., Kaiser M., Pemberton I. and Bode H. B. (2014), Facile Synthesis of Cyclo-
hexanediones and Dialkylresorcinols–Bioactive Natural Products from Entomopathogenic Bacteria.
Eur. J. Org. Chem., 2014: 8026–8028.
68. Kowieski T. M.; Lee S.; Denu J. M. Acetylation-dependent ADP-ribosylation by Trypanosoma brucei
Sir2. J Biol Chem, 2008, 283(9), 5317–5326. https://doi.org/10.1074/jbc.M707613200 PMID:
18165239
69. Borra M. T.; Langer M. R.; Slama J. T.; Denu J. M. Substrate specificity and kinetic mechanism of the
Sir2 family of NAD+-dependent histone/protein deacetylases. Biochemistry, 2004, 43(30), 9877–9887.
https://doi.org/10.1021/bi049592e PMID: 15274642
70. North B. J.; Marshall B. L.; Borra M. T.; Denu J. M.; Verdin E. The Human Sir2 Ortholog, SIRT2, Is an
NAD+-Dependent Tubulin Deacetylase. Molecular Cell, 2003, 11(2), 437–444. PMID: 12620231
71. Avalos J. L.; Bever K. M.; Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the
NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell, 2005, 17(6), 855–868. https://doi.org/10.
1016/j.molcel.2005.02.022 PMID: 15780941
72. Chakrabarty S. P.; Saikumari Y. K.; Bopanna M. P.; Balaram H. Biochemical characterization of Plas-
modium falciparum Sir2, a NAD+-dependent deacetylase. Mol Biochem Parasitol, 2008, 158(2), 139–
151. https://doi.org/10.1016/j.molbiopara.2007.12.003 PMID: 18221799
73. Soares M. B.; Silva C. V.; Bastos T. M.; Guimaraes E. T.; Figueira C. P.; Smirlis D.; Azevedo W. F. Jr.
Anti-Trypanosoma cruzi activity of nicotinamide. Acta Trop, 2012, 122(2), 224–229. https://doi.org/10.
1016/j.actatropica.2012.01.001 PMID: 22281243
74. Tavares J.; Ouaissi A.; Silva A. M.; Lin P. K.; Roy N.; Cordeiro-da-Silva A. Anti-leishmanial activity of
the bisnaphthalimidopropyl derivatives. Parasitol Int, 2012, 61(2), 360–363. https://doi.org/10.1016/j.
parint.2011.11.005 PMID: 22155672
75. Zhang J. H.; Chung T. D.; Oldenburg K. R. A Simple Statistical Parameter for Use in Evaluation and Val-
idation of High Throughput Screening Assays. J Biomol Screen, 1999, 4(2), 67–73. https://doi.org/10.
1177/108705719900400206 PMID: 10838414
Inhibitors of TcSir2rp1 for Chagas disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006180 January 22, 2018 29 / 30
76. Moraes C. B.; Giardini M. A.; Kim H.; Franco C. H.; Araujo-Junior A. M.; Schenkman S.; Chatelain E.;
Freitas-Junior L. H. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against
Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep, 2014,
4.
77. Mingatto F. E.; Rodrigues T.; Pigoso A. A.; Uyemura S. A.; Curti C.; Santos A. C. The critical role of
mitochondrial energetic impairment in the toxicity of nimesulide to hepatocytes. J Pharmacol Exp Ther,
2002, 303(2), 601–607. https://doi.org/10.1124/jpet.102.038620 PMID: 12388641
78. Tripathi R.; Tripathi P.; Pancholi S. S.; Patel C. N. The genotoxic and cytotoxic effects of nimesulide in
the mouse bone marrow. Drug Chem Toxicol, 2014, 37(3), 255–260. https://doi.org/10.3109/
01480545.2013.838779 PMID: 24164450
79. Borkotoky D.; Panda S. K.; Sahoo G. R.; Parija S. C. Genotoxicity of nimesulide in Wistar rats. Drug
Chem Toxicol, 2014, 37(2), 178–183. https://doi.org/10.3109/01480545.2013.834357 PMID:
24116684
80. Religa A. A.; Waters A. P. Sirtuins of parasitic protozoa: in search of function(s). Mol Biochem Parasitol,
2012, 185(2), 71–88. https://doi.org/10.1016/j.molbiopara.2012.08.003 PMID: 22906508
81. Zheng W. Sirtuins as emerging anti-parasitic targets. Eur J Med Chem, 2013, 59, 132–140. https://doi.
org/10.1016/j.ejmech.2012.11.014 PMID: 23220641
82. Li F.; Chong Z. Z.; Maiese K. Cell Life versus cell longevity: the mysteries surrounding the NAD+ precur-
sor nicotinamide. Curr Med Chem, 2006, 13(8), 883–895. PMID: 16611073
83. Prusty D.; Mehra P.; Srivastava S.; Shivange A. V.; Gupta A.; Roy N.; Dhar S. K. Nicotinamide inhibits
Plasmodium falciparum Sir2 activity in vitro and parasite growth. FEMS Microbiol Lett, 2008, 282(2),
266–272. https://doi.org/10.1111/j.1574-6968.2008.01135.x PMID: 18397290
84. Sereno D.; Alegre A. M.; Silvestre R.; Vergnes B.; Ouaissi A. In vitro antileishmanial activity of nicotin-
amide. Antimicrob Agents Chemother, 2005, 49(2), 808–812. https://doi.org/10.1128/AAC.49.2.808-
812.2005 PMID: 15673775
85. Unciti-Broceta J. D.; Maceira J.; Morales S.; Garcia-Perez A.; Munoz-Torres M. E.; Garcia-Salcedo J.
A. Nicotinamide inhibits the lysosomal cathepsin b-like protease and kills African trypanosomes. J Biol
Chem, 2013, 288(15), 10548–10557. https://doi.org/10.1074/jbc.M112.449207 PMID: 23443665
86. Ralton L.; Bestwick C. S.; Thoo Lin P. K. Polyamine Analogues and Derivatives as Potential Anticancer
Agents. Current Bioactive Compounds, 2007, 3(3), 179–191.
87. Braña M. F.; Castellano J. M.; Mora´n M.; Pe´rez de Vega M. J.; Qian X. D.; Romerdahl C. A.; Keilhauer
G. Bis-naphthalimides. 2. Synthesis and biological activity of 5,6-acenaphthalimidoalkyl-1,8-naphthali-
midoalkyl amines. European Journal of Medicinal Chemistry, 1995, 30(3), 235–239.
88. Roy Chowdhury A.; Bakshi R.; Wang J.; Yildirir G.; Liu B.; Pappas-Brown V.; Tolun G.; Griffith J. D.;
Shapiro T. A.; Jensen R. E.; Englund P. T. The killing of African trypanosomes by ethidium bromide.
PLoS Pathog, 2010, 6(12), e1001226. https://doi.org/10.1371/journal.ppat.1001226 PMID: 21187912
89. Prieto G.; Fullaondo A.; Rodriguez J. A. Prediction of nuclear export signals using weighted regular
expressions (Wregex). Bioinformatics, 2014, 30(9), 1220–1227. https://doi.org/10.1093/bioinformatics/
btu016 PMID: 24413524
90. Kosugi S.; Hasebe M.; Tomita M.; Yanagawa H. Systematic identification of cell cycle-dependent yeast
nucleocytoplasmic shuttling proteins by prediction of composite motifs. Proc Natl Acad Sci U S A, 2009,
106(25), 10171–10176. https://doi.org/10.1073/pnas.0900604106 PMID: 19520826
91. Owens J. Determining druggability. Nat Rev Drug Discov, 2007, 6(3), 187–187.
Inhibitors of TcSir2rp1 for Chagas disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006180 January 22, 2018 30 / 30
